Risk factors for non-alcoholic fatty liver disease-associated hepatic fibrosis in type 2 diabetes patients

[21] Choi KC(2005)Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients J Hepatol 42 41-638

[22] Chang Y(2011)Insulin resistance and chronic liver disease World J Hepatol 3 99-130

[23] Jung H-S(2001)High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis Hepatology 34 738-2187

[24] Yun KE(2017)A practical review of C-peptide testing in diabetes Diabetes Ther 8 475-875

[25] Cho J(2018)C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population World J Gastroenterol 24 3663-804

[26] Cho YK(2013)Sensitive and specific time-resolved fluorescence immunoassay of rat C-peptide for measuring hormone secretory and storage capacity of β-cells in vivo and in vitro Endocrinology 154 1934-758

[27] Ryu S(2014)Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone Lipids Health Dis 13 7-396

[28] Han E(2016)Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes Diabetes Care 39 632-1287

[29] Lee Y-h(2008)Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes Gastroenterology 135 122-457

[30] Ratziu V(2014)Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis Hepatology 59 2178-19

[21] Choi KC(2005)Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C patients J Hepatol 42 41-638

[22] Chang Y(2011)Insulin resistance and chronic liver disease World J Hepatol 3 99-130

[23] Jung H-S(2001)High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis Hepatology 34 738-2187

[24] Yun KE(2017)A practical review of C-peptide testing in diabetes Diabetes Ther 8 475-875

[25] Cho J(2018)C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population World J Gastroenterol 24 3663-804

[26] Cho YK(2013)Sensitive and specific time-resolved fluorescence immunoassay of rat C-peptide for measuring hormone secretory and storage capacity of β-cells in vivo and in vitro Endocrinology 154 1934-758

[27] Ryu S(2014)Differential patterns of insulin secretion and sensitivity in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease versus patients with type 2 diabetes mellitus alone Lipids Health Dis 13 7-396

[28] Han E(2016)Metabolic impact of nonalcoholic steatohepatitis in obese patients with type 2 diabetes Diabetes Care 39 632-1287

[29] Lee Y-h(2008)Increased liver fat, impaired insulin clearance, and hepatic and adipose tissue insulin resistance in type 2 diabetes Gastroenterology 135 122-457

[30] Ratziu V(2014)Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis Hepatology 59 2178-19